Scholarlink

Background <p>Drug toxicity with respect to adverse drug reactions (ADRs) poses a substantial barrier to meeting global healthcare demands, impacting both the recovery of patients and the economic aspects of healthcare systems. Studies have consistently demonstrated the potential toxicity of the combination of anti-tubercular (anti-TB) drugs, such as isoniazid, rifampicin, and pyrazinamide.</p> Methodology <p>In the present study, Wistar rats have been divided into four groups, namely the GI—control group, GII—the drugs group (combination of anti-TB drugs, i.e., isoniazid + rifampicin + pyrazinamide), GIII—<i>B. aristata</i> group, and GIV—treatment groups (anti-TB drugs + <i>B. aristata</i>) orally for 28&#xa0;days.</p> Results <p>The groups exposed to the combination of anti-TB drugs exhibited a significant decrease in hemoglobin concentration and total leukocyte count. In contrast, supplementation with <i>B. aristata</i> resulted in a significant restoration of physiological alterations compared to the drugs group. Scanning electron microscopy revealed significant alterations in the topography of erythrocytes, including acanthocytes, echinocytes, and stomatocytes, in the drugs group, which were observed to be mitigated in the <i>B. aristata</i> group.</p> Conclusion <p>These findings underscore both the impact of anti-TB drugs and <i>B. aristata</i> as a supplement to counter the negative impact.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hematological and ultrastructural toxicity of first-line anti-tuberculosis drugs and the ameliorative effects of Berberis aristata in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月22日

查看全文
  • Radhika Sharma,
  • Yogita Thakur,
  • Seema Rani,
  • Reshma Sinha,
  • Vijay Lakshmi Sharma

摘要

Background

Drug toxicity with respect to adverse drug reactions (ADRs) poses a substantial barrier to meeting global healthcare demands, impacting both the recovery of patients and the economic aspects of healthcare systems. Studies have consistently demonstrated the potential toxicity of the combination of anti-tubercular (anti-TB) drugs, such as isoniazid, rifampicin, and pyrazinamide.

Methodology

In the present study, Wistar rats have been divided into four groups, namely the GI—control group, GII—the drugs group (combination of anti-TB drugs, i.e., isoniazid + rifampicin + pyrazinamide), GIII—B. aristata group, and GIV—treatment groups (anti-TB drugs + B. aristata) orally for 28 days.

Results

The groups exposed to the combination of anti-TB drugs exhibited a significant decrease in hemoglobin concentration and total leukocyte count. In contrast, supplementation with B. aristata resulted in a significant restoration of physiological alterations compared to the drugs group. Scanning electron microscopy revealed significant alterations in the topography of erythrocytes, including acanthocytes, echinocytes, and stomatocytes, in the drugs group, which were observed to be mitigated in the B. aristata group.

Conclusion

These findings underscore both the impact of anti-TB drugs and B. aristata as a supplement to counter the negative impact.

Graphical Abstract